Navigation Links
Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
Date:6/8/2009

from the ITCA 650 phase 1b study have provided important guidance toward dose selection and study design for continuing clinical development," said Kenneth L. Luskey, MD, VP Clinical Research at Intarcia. "A phase 2 study of ITCA 650 is planned for the third quarter of this year. In this trial we intend to confirm the Phase 1b results on a larger scale and for a longer duration to further characterize the glucose lowering effects and tolerability of ITCA 650."

ITCA 650 therapy in this phase 1b trial was administered for the full course of treatment with a single insertion of the ITCA 650 on day 1 and removal on day 29. The phase 2 trial will evaluate ITCA 650 against the current standard of care for a longer duration of treatment and among a larger population of type 2 diabetes patients. The goals of the ITCA 650 program are to enhance the therapeutic effects of exenatide by ensuring patient compliance and providing more consistent, round-the-clock therapeutic drug levels; and to reduce side effects, including nausea associated with high peak levels of exenatide exposure observed with repeated injections.

About ITCA 650

ITCA 650 therapy for type 2 diabetes consists of DUROS continuous delivery of exenatide. The DUROS delivery technology comprises the DUROS device, a matchstick-size miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. The DUROS technology can deliver up to a full year of therapy from a single ITCA 650 insertion. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if required. Exenatide, the active agent in ITCA 650, has been approved in t
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
2. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
3. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
9. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Miami, FL (PRWEB) May 26, 2015 ... training, Inc. have announced plans for the company’s first ... 9, 2015, followed by a full day, hands-on stem ... hosted by J. Victor Garcia Gimenez, M.D., President of ... to the medical community’s increasing interest in regenerative medicine ...
(Date:5/26/2015)... ORANGEBURG, N.Y. , May 26, 2015 /PRNewswire/ ... products and solutions, today announced that Oakwood Healthcare ... been selected as the winning entry in ... recognizing industry professionals who display excellence in building ... services (ES) teams in healthcare facilities.  ...
(Date:5/26/2015)... ANGELES , May 26, 2015 Pharmaco-Kinesis ... Board (NOCAB) recently convened at Shutters on the Beach ... review the development status of the Company,s innovative Metronomic ... designed to locally deliver chemotherapy over time to a ... dose delivery capacity and biofeedback system in real-time.  ...
(Date:5/26/2015)... 2015 Kevin Xu , prezident ... Barackovi Obamovi a Billovi Clintonovi za ich kondolencie ... Rongxiang Xu , otca Kevina. ... Dr. Xu bol pionier, inovátor, humanitárny pracovník a ... oblasti vedy a príkladné vedenie svojej komunity zanecháva ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, O legende 2
... 16 /PRNewswire-Asia-FirstCall/ -- A-Power Energy,Generation Systems, Ltd. (Nasdaq: ... of distributed power generation ("DG") systems in China and ... signed a,contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. ... Province of,China. , Pursuant to ...
... SYDNEY, June 16 /PRNewswire-Asia/ -- Pharmaceutical company ... announce that additional results of its,recently completed international Phase III ... at the 2009 European Cystic Fibrosis,Conference in Brest, France. , ... conference on Friday 12 June by Dr Diana,Bilton of the ...
... Sharoky, M.D. to Assume the Role of Chairman of the ... Insmed Inc. (Nasdaq: INSM ), a biopharmaceutical company, ... President, Chief Executive Officer and Chairman of the Board of ... Allan has served as Insmed,s President, Chief Executive Officer and ...
Cached Biology Technology:A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. 2A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 4Insmed CEO Resigns Due to Health Concerns 2Insmed CEO Resigns Due to Health Concerns 3
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... E supplements may blunt the improvement of muscular endurance ... new study published today [3 February] in The Journal ... widely used, understanding if they interfere with cellular and physiological ... health purposes as well as to athletes., Dr Gran Paulsen, ...
... Immune cells undergo ,spontaneous, changes on a daily basis ... diligent surveillance of our immune system, Melbourne scientists have ... Eliza Hall Institute found that the immune system was ... their early stages, before they developed into B-cell lymphomas ...
... In many people with autism and other neurodevelopmental disorders, ... other very well. Scientists have now identified, for the ... connectivity can come about. In a study published online ... European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, and ...
Cached Biology News:Vitamin C and E supplements hampers endurance training 2Red alert: Body kills 'spontaneous' blood cancers on a daily basis 2Making your brain social 2